They presented: long-term follow-up results of MBC patients who achieved complete remission (CR) after treatment with doxorubicin and alkylating agents’ chemotherapy regimen; the correlation between amplification of HER-2/neu in human breast cancer cells and recurrence and survival; detection and characterization of CTCs levels in peripheral blood of breast cancer patients before and after neoadjuvant therapy. This evidence concerns the gene ERBB2 and breast cancer.